Posted by Michael Wonder on 30 Aug 2018
ICER finds current list price of patisiran for amyloidosis far exceeds standard cost-effectiveness levels
29 August 2018 - Report also evaluates evidence on inotersen; during public meeting of Midwest CEPAC on 13 September, a policy roundtable will discuss possible contextual factors that may affect decision-making for ultra-rare conditions such as amyloidosis.
ICER today released an evidence report assessing the comparative clinical effectiveness and value of therapies to treat hereditary transthyretin amyloidosis. The report includes inotersen (Akcea Therapeutics) and patisiran (Onpattro, Alnylam Pharmaceuticals).
Patisiran was recently approved by the FDA. An approval decision on inotersen is expected in October 2018.
